276 related articles for article (PubMed ID: 34215221)
21. ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.
Jung M; Gao J; Cheung L; Bongers A; Somers K; Clifton M; Ramsay EE; Russell AJ; Valli E; Gifford AJ; George J; Kennedy CJ; Wakefield MJ; Topp M; Ho GY; ; Scott CL; Bowtell DD; deFazio A; Norris MD; Haber M; Henderson MJ
Int J Cancer; 2020 Oct; 147(8):2225-2238. PubMed ID: 32277480
[TBL] [Abstract][Full Text] [Related]
22. Non-classical estrogen signaling in ovarian cancer improves chemo-sensitivity and patients outcome.
Hao D; Li J; Wang J; Meng Y; Zhao Z; Zhang C; Miao K; Deng C; Tsang BK; Wang L; Di LJ
Theranostics; 2019; 9(13):3952-3965. PubMed ID: 31281524
[TBL] [Abstract][Full Text] [Related]
23. Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
Heinzelmann-Schwarz V; Knipprath Mészaros A; Stadlmann S; Jacob F; Schoetzau A; Russell K; Friedlander M; Singer G; Vetter M
Gynecol Oncol; 2018 Jan; 148(1):79-85. PubMed ID: 29157627
[TBL] [Abstract][Full Text] [Related]
24. TRAF4 promotes the malignant progression of high-grade serous ovarian cancer by activating YAP pathway.
Luo X; Cao J; Zhang C; Huang H; Liu J
Biochem Biophys Res Commun; 2022 Oct; 627():68-75. PubMed ID: 36029535
[TBL] [Abstract][Full Text] [Related]
25. A Study of High-Grade Serous Ovarian Cancer Origins Implicates the SOX18 Transcription Factor in Tumor Development.
Lawrenson K; Fonseca MAS; Liu AY; Segato Dezem F; Lee JM; Lin X; Corona RI; Abbasi F; Vavra KC; Dinh HQ; Gill NK; Seo JH; Coetzee S; Lin YG; Pejovic T; Mhawech-Fauceglia P; Rowat AC; Drapkin R; Karlan BY; Hazelett DJ; Freedman ML; Gayther SA; Noushmehr H
Cell Rep; 2019 Dec; 29(11):3726-3735.e4. PubMed ID: 31825847
[TBL] [Abstract][Full Text] [Related]
26. Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.
Jönsson JM; Johansson I; Dominguez-Valentin M; Kimbung S; Jönsson M; Bonde JH; Kannisto P; Måsbäck A; Malander S; Nilbert M; Hedenfalk I
PLoS One; 2014; 9(9):e107643. PubMed ID: 25226589
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA Expression Profiling of Epithelial Ovarian Cancer Identifies New Markers of Tumor Subtype.
Rattanapan Y; Korkiatsakul V; Kongruang A; Siriboonpiputtana T; Rerkamnuaychoke B; Chareonsirisuthigul T
Microrna; 2020; 9(4):289-294. PubMed ID: 32703147
[TBL] [Abstract][Full Text] [Related]
28. [Bioinformatics analysis of drug-resistant ceRNA in epithelial ovarian cancer].
Pan ZM; Tan FC; Chen CX; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2021 Feb; 56(2):121-130. PubMed ID: 33631884
[No Abstract] [Full Text] [Related]
29. Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance Treatment.
Vetter M; Stadlmann S; Bischof E; Georgescu Margarint EL; Schötzau A; Singer G; Heinzelmann-Schwarz V; Montavon C
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430718
[TBL] [Abstract][Full Text] [Related]
30. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J
Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232
[TBL] [Abstract][Full Text] [Related]
31. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
33. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
Murumägi A; Ungureanu D; Khan S; Arjama M; Välimäki K; Ianevski A; Ianevski P; Bergström R; Dini A; Kanerva A; Koivisto-Korander R; Tapper J; Lassus H; Loukovaara M; Mägi A; Hirasawa A; Aoki D; Pietiäinen V; Pellinen T; Bützow R; Aittokallio T; Kallioniemi O
Br J Cancer; 2023 Feb; 128(4):678-690. PubMed ID: 36476658
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide expression profiling reveals novel biomarkers in epithelial ovarian cancer.
Gautam P; Gupta S; Sachan M
Pathol Res Pract; 2023 Nov; 251():154840. PubMed ID: 37844484
[TBL] [Abstract][Full Text] [Related]
35. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract][Full Text] [Related]
36. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
[TBL] [Abstract][Full Text] [Related]
37. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
38. The Cell-Free Expression of MiR200 Family Members Correlates with Estrogen Sensitivity in Human Epithelial Ovarian Cells.
Márton É; Varga A; Széles L; Göczi L; Penyige A; Nagy B; Szilágyi M
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33419253
[TBL] [Abstract][Full Text] [Related]
39. Expression and clinical significance of estrogen-regulated long non-coding RNAs in estrogen receptor α-positive ovarian cancer progression.
Qiu JJ; Ye LC; Ding JX; Feng WW; Jin HY; Zhang Y; Li Q; Hua KQ
Oncol Rep; 2014 Apr; 31(4):1613-22. PubMed ID: 24481591
[TBL] [Abstract][Full Text] [Related]
40. Gene expression profiling of epithelial ovarian cancer reveals key genes and pathways associated with chemotherapy resistance.
Zhang M; Luo SC
Genet Mol Res; 2016 Jan; 15(1):. PubMed ID: 26909918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
